Completed PHASE2 INTERVENTIONAL 8-arm NCT06212648

Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension (SP-CAP-002)

A Multi-center, Randomized, Double-blind, Parallel, Phase 2 Clinical Trial to Compare and Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension

Sponsor: Shin Poong Pharmaceutical Co. Ltd.

Conditions Essential Hypertension Hypertension

Interventions Placebo SPC1001 High SPC1001 Low SPC1001 Mid1 SPC1001 Mid2 SPC3001 SPC4001 SPC4002

Updated 4 times since 2024 Last updated: Jan 8, 2024 Started: Mar 25, 2022 Primary completion: Nov 27, 2022 Completion: Jan 27, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06212648, this PHASE2 trial focuses on Essential Hypertension and Hypertension and remains completed. Sponsored by Shin Poong Pharmaceutical Co. Ltd., it has been updated 4 times since 2022, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

4 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Feb 2024 — Jul 2024 [monthly]

Completed PHASE2

First recorded

Mar 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shin Poong Pharmaceutical Co. Ltd.

Data source: Shin Poong Pharmaceutical Co. Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea